Research programme: therapeutic antibody fragments - Kuur Therapeutics
Alternative Names: DLX-1008; DLX-212; DLX-2201; DLX-2681; DLX-2751; DLX-2882/3003; DLX-521; DLX-903; DLX-903/1008Latest Information Update: 11 May 2021
At a glance
- Originator Delenex Therapeutics
- Developer Kuur Therapeutics
- Class Antibodies
- Mechanism of Action Amyloid beta-protein inhibitors; Anaplastic lymphoma kinase inhibitors; Interleukin 1 beta inhibitors; Interleukin 12 inhibitors; Interleukin 17 inhibitors; Interleukin 23 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acne; Cancer; Glioblastoma; Gout; Hidradenitis suppurativa; Inflammatory bowel diseases; Kaposi's sarcoma; Neurological disorders; Psoriasis; Pyoderma; Skin disorders
Most Recent Events
- 04 May 2021 Kuur Therapeutics has been acquired by Athenex
- 10 Mar 2020 Cell Medica is now called Kuur Therapeutics
- 28 Nov 2019 No recent reports of development identified for preclinical development in Acne in Switzerland (SC)